Navigation Links
Celebrex inhibited the burden of skin cancer in high-risk patients
Date:1/4/2010

PHILADELPHIA People with the heritable disorder of the skin called Gorlin syndrome who are genetically predisposed to develop basal cell carcinoma of the skin may have a new chemoprevention therapy on the horizon.

According to results of a placebo-controlled, randomized, double-blind, Phase II study, the use of celecoxib was effective in inhibiting the development of basal cell carcinomas in a relatively rare group of patients who are highly susceptible to carcinoma. These findings are published in the January issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

Celecoxib, sold under the brand name of Celebrex by Pfizer Inc., is a non-steroidal anti-inflammatory drug (NSAID). Patients with Gorlin syndrome typically develop hundreds or even thousands of basal cell carcinomas in their lifetime.

Ervin H. Epstein Jr., M.D., senior scientist at the Children's Hospital of Oakland Research Institute, Oakland, Calif., said the goal of this study was to reduce the number of basal cell carcinomas in patients with this rare disorder who are most at risk for this form of cancer.

"The underlying idea is if we can find something in these high-risk patients that could be translatable to the 'normal' population, then we could ultimately use that form of chemoprevention to reduce the numbers of skin cancer in all people," he said.

Epstein and colleagues randomized 60 patients with basal cell carcinoma to receive either 200 mg of oral celecoxib two times a day or placebo. After about two years, patients who received placebo had a 50 percent increase in basal cell carcinoma per year compared with a 20 percent increase among those who received celecoxib.

"We found some beneficial effect of preventing tumors in patients treated with the NSAID," Epstein said.

Furthermore, there was no difference in the rate or severity of side effects between patients in either g
'/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert  

Page: 1 2

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. Poor Americans in the United States suffer hidden burden of parasitic and other neglected diseases
3. NTDs burden in Latin America and the Caribbean may exceed that of HIV/AIDS, TB and malaria
4. Fighting the burden of mental disorders
5. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. ESF EURYI award winner aims to stop cancer cells reading their own DNA
8. Protein chatter linked to cancer activation
9. Newly created cancer stem cells could aid breast cancer research
10. Western diet linked to increased risk of colon cancer recurrence
11. Obesity and lack of exercise could enhance the risk of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex inhibited the burden of skin cancer in high-risk patients
(Date:7/23/2014)... International Journal of Fuzzy Systems ( IJFS ... Association (TFSA). The cooperation will allow the journal to ... research., The International Journal of Fuzzy Systems ... the theory, design and application of fuzzy systems, soft ... from hardware to software. Launched in 1999, the quarterly ...
(Date:7/23/2014)... principal bacteria that cause dental caries, has increased ... possibly coinciding with dietary change linked to the ... a study by researchers from the Universitat Autnoma ... Genmica para la Biodiversidad (National Laboratory of Genomics ... time, have sequenced genetic material from this bacterium ...
(Date:7/23/2014)... equipment, trained personnel, and detection dogs to safeguard ... A revolutionary new electronic chip with nano-sized chemical ... easier. , The groundbreaking nanotechnology-inspired sensor, devised by ... School of Chemistry and Center for Nanoscience and ... picks up the scent of explosives molecules better ...
Breaking Biology News(10 mins):Ancient genetic material from caries bacterium obtained for the first time 2Nano-sized chip "sniffs out" explosives far better than trained dogs 2
... identified a specific class of pharmaceutical drugs that could ... Death Syndrome (SIDS), because their mothers smoked during pregnancy. ... the fetus to nicotine results in the inability to ... in a higher incidence of SIDS. In the ...
... recent years, obesity has taken on epidemic proportions in ... death and rising health care costs. According to Centers ... quarter of all American adults and more than 15 ... While recent research advances and treatment methods ...
... collaboration research carried out by the teams of Jordi ... and ngel Raya, Centre for Regenerative Medicine of Barcelona ... and Technological Research (CIEMAT), has resulted in the generation ... a genetic disease known as Fanconi anemia. The process ...
Cached Biology News:Simple drug treatment may prevent nicotine-induced SIDS: Study 2Researchers engineer metabolic pathway in mice to prevent diet-induced obesity 2Researchers engineer metabolic pathway in mice to prevent diet-induced obesity 3Genetically corrected blood cells obtained from skin cells from Fanconi anemia patients 2
(Date:7/23/2014)... (PRWEB) July 23, 2014 OncLive® ... Cancer Center has joined its Strategic Alliance Partnership ... Alliance Partnership program, UNC Lineberger will have the ... raise awareness of its cutting-edge research initiatives, community-directed ... UNC Lineberger will work with OncLive to educate ...
(Date:7/23/2014)... 23, 2014 Adult stem cells ... are biological, but not magical. However, many ... treat them as if they were magical. , ... studies that constitute “stem cell tourism,” are evaluating ... to developing new regenerative medicine therapies. In reality, ...
(Date:7/22/2014)... NJ (PR Web) July 21, 2014 (PRWEB) July ... Center for Biomaterials, at Rutgers University. , ... information and ideas across the full spectrum of ... on selected research and development topics that represent ... Activities have been programmed to:, ...
(Date:7/22/2014)... 22, 2014 Even within a phylum so full of ... among other arthropods for its cruelty -- at least to ... the fly is a most predatory sort of parasite. It ... a smear of larvae, and leaves its wicked brood to ... , None of this would be possible without the fly,s ...
Breaking Biology Technology:OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4
... Inc. (Nasdaq: IDIX ) announced today that management ... programs at the Canaccord Adams Hepatitis C Conference on Tuesday, ... Barclay New York Hotel in New York City.The live and ... of Events" in the Idenix Investor Center at ...
... Agent to Find Partner to Co-Develop Company,s Chinese ... VEGAS, April 3 ... "Company") is pleased to announce that it ... an international marketing organization headquartered in New Jersey ...
... ChromaDex Corporation, (OTC Bulletin Board: CDXC) a ... today announced financial results for the 2008 Fiscal ... with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ... stockholders of $0.07 per share for the twelve ...
Cached Biology Technology:Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier 2ChromaDex Announces 2008 Year End Financial Results 2ChromaDex Announces 2008 Year End Financial Results 3